Article Information
PubMed
Print ISSN
Online ISSN
History
- Received January 12, 2022
- Accepted May 5, 2022
- Published online August 1, 2022.
Article Versions
- Earlier version (June 14, 2022 - 12:17).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2022 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license.
Author Information
- Jonathan N. Bauman,
- Angela C. Doran,
- Amanda King-Ahmad,
- Raman Sharma,
- Gregory S. Walker,
- Jian Lin,
- Tsung H. Lin,
- Jean-Baptiste Telliez,
- Sakambari Tripathy,
- Theunis C. Goosen,
- Christopher Banfield,
- Bimal K. Malhotra, and
- Martin E. Dowty
- Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)
- Address correspondence to:
Martin E. Dowty, Pfizer Inc., 1 Portland St, Cambridge, MA 02139. E-mail: martin.dowty{at}pfizer.com